Data from Phase 2 ACE Study of Ambit's Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia Presented at 18th Congress of the European Hematology Association Data from Phase 2 ACE Study of Ambit's Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia Presented at 18th Congress of the European Hematology ... (more)
http://www.appliedclinicaltrialsonline.com/appliedclinicaltrials/Phase+News/Data-from-Phase-2-ACE-Study-of-Ambits-Quizartinib-/ArticleNewsFeed/Article/detail/816799?ref=25
http://www.appliedclinicaltrialsonline.com/appliedclinicaltrials/Phase+News/Data-from-Phase-2-ACE-Study-of-Ambits-Quizartinib-/ArticleNewsFeed/Article/detail/816799?ref=25
No comments:
Post a Comment